Prices and availability of pharmaceuticals: evidence from nine countries.
نویسندگان
چکیده
This study compares average price levels for pharmaceuticals in eight countries--Canada, Chile, France, Germany, Italy, Japan, Mexico, and the United Kingdom--relative to the United States. Our most comprehensive indexes, adjusted for U.S. manufacturer discounts, show Japan's prices to be higher than U.S. prices, and other countries' prices ranging from 6 percent to 33 percent lower than U.S. prices. The decline of the Canadian dollar and rise of the U.K. pound contribute to the finding of lower Canadian prices and higher U.K. prices in 1999 than in 1992. Our findings suggest that U.S.-foreign price differentials are roughly in line with income and smaller for drugs than for other medical services.
منابع مشابه
The prices outpatients have to pay for purchasing medicines in Armenia
Background The great majority of patients in lowand middle-income countries purchase medicines out of pocket. Correspondingly, pharmaceuticals, especially those which are high cost, can be unaffordable for patients. Measuring medicine availability and prices is especially important for countries like Armenia, which are still not implementing policy for managing prices of pharmaceuticals. The ob...
متن کاملمقایسه نظام قیمت گذاری و بیمه دارو در ایران و کشورهای منتخب
Introduction: Pharmaceuticals comprise a large portion of health care expenditures, including insurance organizations expenditures. Accumulated evidence suggests that the inefficiencies of Iran's health insurance structure have led to soaring out- of- pocket payments by the beneficiaries of health insurance organizations. This study was conducted to compare pricing and reimbursement of pharmace...
متن کاملReference pricing of pharmaceuticals for Medicare: evidence from Germany, The Netherlands, and New Zealand.
This paper describes three prototypical systems of therapeutic reference pricing (RP) for pharmaceuticals--Germany, the Netherlands, and New Zealand--and examines their effects on the availability of new drugs, reimbursement levels, manufacturer prices, and out-of-pocket surcharges to patients. RP for pharmaceuticals is not simply analogous to a defined contribution approach to subsidizing insu...
متن کاملReference Pricing of Pharmaceuticals: Evidence from Germany, the Netherlands and New Zealand
This paper describes three prototypical systems of therapeutic reference pricing (RP) for pharmaceuticals -Germany, the Netherlands, and New Zealand -and examines their effects on the availability of new drugs; manufacturer prices, reimbursement levels, and out-of-pocket surcharges to patients; and market shares of originator and generic products. The results differ across countries in predicta...
متن کاملNber Working Paper Series Reference Pricing of Pharmaceuticals for Medicare: Evidence from Germany, the Netherlands and New Zealand
This paper describes three prototypical systems of therapeutic reference pricing (RP) for pharmaceuticals -Germany, the Netherlands, and New Zealand -and examines their effects on the availability of new drugs, reimbursement levels, manufacturer prices and out-of-pocket surcharges to patients. RP for pharmaceuticals is not simply analogous to a defined contribution approach to subsidizing insur...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Health affairs
دوره Suppl Web Exclusives شماره
صفحات -
تاریخ انتشار 2003